Sinopharm Group

BEIJING, Dec. 4, 2023 /PRNewswire/ -- This is a report from China.org.cn about health innovations at China Int'l Supply Chain Expo: At a dental clinic at the China Int'l Supply Chain Expo, you can take advantage of a free dental check. The 360° view allows you to see all around your entire mouth including the cracks and cavities. You can even see the coloring on your teeth. It's an amazing technology of Sinopharm! Continue Reading This video shows delicious diet food, magical “sleep enhancer” and an impressive dental device. They are among the exhibits in the Healthy Life section at the 1st China Int'l Supply Chain Expo. Watch it and unlock the secrets of a healthy life! Also at the Sinopharm pavilion, I have tasted some cookies. "It belongs to low-GI foods, meaning it has a low glycemic index. Therefore, it's particularly suitable for people with diabetes, fitness enthusiasts and those looking to lose weight", said the Lv Yuting of Sinopharm Healthcare Industry Company. "It's extra thin, extra crispy and delicious." One of the highlights of this exhibition is Sinopharm Imaging, a joint venture between Sinopharm with GE Healthcare. "The Sinopharm Imaging mainly produces high-end medical equipment, including CT, MRI and ultrasound devices. These are widely used in major top-tier hospitals", said Zhang Junyue, Executive Director of the Dept. of Industrial Development and Research Management of Sinopharm. At this supply chain expo, GE Healthcare is showcasing the key core components of their entire supply chain. "Through the expo, we hope to bring together suppliers from upstream to downstream, leveraging our country's advantages of increasing openness and diverse industrial categories, to foster a better prospect for common development," said Chen Heqiang, GE HealthCare China Supply Chain General Manager. Beyond American firms, Chinese pharmaceutical supply chain also collaborates closely with companies from other countries, including a Swiss company named dsm-firmenich, which produces HMO (Human Milk Oligosaccharides). "It can more effectively promote beneficial bacteria in infants' intestinal tracts, helping to establish a protective barrier in the gut", said Annie Li of dsm-firmenich. The pharmaceutical industry chain is a constant companion throughout our lives, from birth to old age. SOURCE China.org.cn

Ansun Biopharma closed on a Series A financing round worth $85 million. The company plans to use the funds raised for a Phase III clinical trial of its experimental anti-viral drug, DAS181. Ansun Biopharma , based in San Diego, closed on a Series A financing round worth $85 million. The round was led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, and Joincap Investment. The company plans to use the funds raised for a Phase III clinical trial of its experimental anti-viral drug, DAS181. The U.S. Food and Drug Administration (FDA) gave the drug Breakthrough Therapy Designations in October 2017, for the treatment of lower respiratory tract parainfluenza virus (PIV) infection in patients who are immunocompromised. It also received Fast Track designation. DAS181 takes a unique host-directed approach to blocking respiratory viruses. It cleaves sialic acid receptors in the human respiratory tract, which are linked by most of the major respiratory viruses during infection. It has shown antiviral activity in three of the four major respiratory viruses, influenza virus (IFV), parainfluenza virus (PIV) and metapneumovirus (MPV), as well as human enterovirus-68 (EV-68). The way it acts makes it more difficult for viruses to depend on sialic acid receptor. Late last year it completed a Phase II trial of DAS181 for PIV infection in hospitalized, immunocompromised patients. The company has also worked with the FDA to make the compound available for treatment of more than 130 pediatric and adult patients through its compassionate use program. “We are excited about this designation and a look forward to continuing to work closely with the Division of Antiviral products at the FDA as we plan and implement a Phase III study for this severely ill patient population,” said George Wang, Ansun’s chief technical officer, in an October 2017 statement. In addition to the financing, Xiaoming Yang from Sinopharm Capital and Yi Shi from Lilly Asia Ventures are joining Ansun’s board of directors. Donald Payne and Michael Chao are also joining the board. Existing board members are Allen Chao, Nancy Chang and Michael Chang. “We are delighted to secure this strong financial support from some of the most highly regarded biotechnology investment groups in the world,” said Nancy Chang, Ansun’s interim chief executive officer, in a statement. “And just as important, if not more important, than their financial support is the depth of knowledge and experience our board will gain with our new board members.” About 55,000 to 200,000 patients in hospital in the U.S. are diagnosed with PIV annually. They are often in immunocompromised patients including those undergoing chemotherapy, solid organ transplants and hematopoietic stem cell transplants. If DAS181 makes it through Phase III trials and is approved, it could become the first product specifically approved for this medical need. The company has two programs. One is for influenza, the other is for the PIV infections. “We are very pleased to be leading this round in Ansun against a backdrop of increasing threat worldwide from very dangerous respiratory infectious diseases like influenza and parainfluenza,” Xiaoming Yang said in a statement. “We look forward to working closely with the company, its board of directors and its management to rapidly progress the development of DAS181 so that it can benefit as many people as quickly as possible.”